ClinicalTrials.gg
Active, not recruitingNCT07284901KaiNETIC-2Updated Oct 6, 2026

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

A Phase 3 interventional study of Ribupatide and Placebo in Obesity With Diabetes and Overweight With Diabetes, sponsored by Kailera. Active, not recruiting at 173 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Kailera · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.

Enrollment
2nd of 16
1,270 · median 142
Started
2026
with 2 others
Phase 3
7 of 16
1 open now
Registered
12th of 16
by date
Lead sponsor
6 of 16
Kailera

Among the 16 studies testing ribupatide in Obesity, this one is the 2nd largest by enrollment, is one of 3 that started in 2026, is one of 7 in phase 3, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ribupatide in Obesity, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on:

  • Percent change in body weight
  • Change in hemoglobin A1c (HbA1c)
03

Conditions studied

  • Obesity With Diabetes
  • Overweight With Diabetes

Keywords

  • Obesity
  • Overweight
  • Ribupatide
  • KAI-9531
  • Glucagon-like peptide-1
  • GLP-1
  • Diabetes
  • Glucose-dependent Insulinotropic Peptide
  • GIP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of type 2 diabetes mellitus (T2DM).
  • Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and/or exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatment naïve if they have an of 6.5% to 7.5%, inclusive.
  • ≥27 kg/m\^2.
  • History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.

Key Exclusion Criteria:

  • Current diagnosis or history of type 1 diabetes mellitus (T1DM) or any other type of diabetes except T2DM.
  • History of diabetic ketoacidosis or hyperosmolar state/coma within 1 year prior to Screening.
  • History of severe hypoglycemia or hypoglycemia unawareness within 1 year prior to Screening.
  • Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, or phentermine.
  • Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to Screening.
  • Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
  • Uncontrolled hypertension or unstable cardiovascular disease.
  • History of chronic or acute pancreatitis.
  • Known gastric emptying abnormality or chronic treatment with medications that directly affect gastrointestinal (GI) motility if taken for >30 days continually within 3 months prior to Screening.
  • History of suicide attempt.
  • History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within 2 years prior to Screening.
  • Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonists, GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, glucagon receptor agonists, or other weight loss medications or treatments aside from diet and exercise within 3 months prior to Screening.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,270 participants (actual)

Study arms

  • Experimental
    Ribupatide: Dose 1

    Participants will receive Dose 1 of ribupatide once weekly.

    Drug: Ribupatide

  • Experimental
    Ribupatide: Dose 2

    Participants will receive Dose 2 of ribupatide once weekly.

    Drug: Ribupatide

  • Experimental
    Ribupatide: Dose 3

    Participants will receive Dose 3 of ribupatide once weekly.

    Drug: Ribupatide

  • Experimental
    Ribupatide: Dose 4

    Participants will receive Dose 4 of ribupatide once weekly.

    Drug: Ribupatide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to ribupatide once weekly.

    Drug: Placebo

Interventions

  • SC Injection

    Also known as: KAI-9531

  • DrugPlacebo

    SC Injection

06

What researchers measure

Primary outcomes

  1. Doses 3 and 4 of Ribupatide Versus Placebo: Percent Change From Baseline in Body Weight at Week 76

    Time frame: Baseline, Week 76

  2. Doses 3 and 4 of Ribupatide Versus Placebo: Change From Baseline in HbA1c at Week 76

    Time frame: Baseline, Week 76

Secondary outcomes

  1. Doses 1 and 2 of Ribupatide Versus Placebo: Percent Change From Baseline in Body Weight at Week 76

    Time frame: Baseline, Week 76

  2. Doses 1 and 2 of Ribupatide Versus Placebo: Change From Baseline in HbA1c at Week 76

    Time frame: Baseline, Week 76

  3. Percentage of Participants with ≥5%, ≥10%, ≥15%, ≥20% and ≥25% Reduction in Body Weight

    Time frame: Baseline, Week 76

  4. Change From Baseline in Waist Circumference

    Time frame: Baseline, Week 76

  5. Change From Baseline in Absolute Body Weight

    Time frame: Baseline, Week 76

  6. Percentage of Participants with HbA1c <7% and ≤6.5%

    Time frame: Baseline, Week 76

  7. Change From Baseline in Fasting Blood Glucose

    Time frame: Baseline, Week 76

  8. Change From Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 76

  9. Percent Change From Baseline in Fasting Triglycerides

    Time frame: Baseline, Week 76

  10. Percent Change From Baseline in Fasting High-density Lipoprotein (HDL)-cholesterol

    Time frame: Baseline, Week 76

  11. Percent Change From Baseline in Fasting Non-HDL-cholesterol

    Time frame: Baseline, Week 76

  12. Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

    Time frame: Baseline, Week 76

  13. Participants with Body Mass Index (BMI) ≥35 Kilograms per Square Meter (kg/m^2): Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 76

  14. Percentage of Participants with ≥30% Reduction in Body Weight

    Time frame: Baseline, Week 76

  15. Change From Baseline in BMI

    Time frame: Baseline, Week 76

  16. Percentage of Participants with HbA1c <5.7%

    Time frame: Baseline, Week 76

  17. Change From Baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline, Week 76

  18. Percent Change From Baseline in Fasting Total Cholesterol

    Time frame: Baseline, Week 76

  19. Percent Change From Baseline in Fasting Low-density Lipoprotein (LDL)-cholesterol

    Time frame: Baseline, Week 76

  20. Percent Change From Baseline in Very Low-density Lipoprotein (VLDL)-cholesterol

    Time frame: Baseline, Week 76

  21. Percent Change From Baseline in Fasting Insulin

    Time frame: Baseline, Week 76

  22. Change From Baseline in Control of Eating Questionnaire (CoEQ) Craving Control Score

    Time frame: Baseline, Week 76

  23. Change From Baseline in CoEQ Positive Mood Score

    Time frame: Baseline, Week 76

  24. Change From Baseline in CoEQ Craving for Sweets Score

    Time frame: Baseline, Week 76

  25. Change From Baseline in CoEQ Craving for Savory Food Score

    Time frame: Baseline, Week 76

  26. Change From Baseline in CoEQ Hunger Score

    Time frame: Baseline, Week 76

  27. Change From Baseline in CoEQ Satiety Score

    Time frame: Baseline, Week 76

  28. Change From Baseline in CoEQ Combined Score

    Time frame: Baseline, Week 76

  29. Change From Baseline in Food Noise Questionnaire (FNQ) Score

    Time frame: Baseline, Week 76

  30. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Week 80

  31. Number of Participants With Anti-drug Antibodies (ADAs)

    Time frame: Up to Week 80

  32. Number of Participants With Neutralizing Antibodies (Nabs)

    Time frame: Up to Week 80

  33. Plasma Concentrations of Ribupatide

    Time frame: Up to Week 76

07

Study locations

173 sites
  • Kailera Clinical Site
    Cullman, Alabama 35055, United States
  • Kailera Clinical Site
    Phoenix, Arizona 85012, United States
  • Kailera Clinical Site
    Sun City, Arizona 85351, United States
  • Kailera Clinical Site
    Little Rock, Arkansas 72205, United States
  • Kailera Clinical Site
    Escondido, California 92025, United States
  • Kailera Clinical Site
    La Mesa, California 91942, United States
  • Kailera Clinical Site
    Montclair, California 91763, United States
  • Kailera Clinical Site
    Northridge, California 91325, United States
  • Kailera Clinical Site
    Oceanside, California 92058, United States
  • Kailera Clinical Site
    Toluca Lake, California 91602, United States
  • Kailera Clinical Site
    Stamford, Connecticut 06905, United States
  • Kailera Clinical Site
    Bradenton, Florida 34209, United States
  • Kailera Clinical Site
    Hollywood, Florida 33024, United States
  • Kailera Clinical Site
    Jupiter, Florida 33458, United States
  • Kailera Clinical Site
    Miami, Florida 33135, United States
  • Kailera Clinical Site
    Miami Lakes, Florida 33016, United States
  • Kailera Clinical Site
    Orange City, Florida 32763, United States
  • Kailera Clinical Site
    Orlando, Florida 32801, United States
  • Kailera Clinical Site
    Orlando, Florida 32803, United States
  • Kailera Clinical Site
    The Villages, Florida 32162, United States
  • Kailera Clinical Site
    Decatur, Georgia 30030, United States
  • Kailera Clinical Site
    Lilburn, Georgia 30047, United States
  • Kailera Clinical Site
    Marietta, Georgia 30060, United States
  • Kailera Clinical Site
    Riverdale, Georgia 30274, United States
  • Kailera Clinical Site
    Skokie, Illinois 60077, United States
  • Kailera Clinical Site
    Springfield, Illinois 62702, United States
  • Kailera Clinical Site
    Newton, Kansas 67114, United States
  • Kailera Clinical Site
    Shreveport, Louisiana 71105, United States
  • Kailera Clinical Site
    Annapolis, Maryland 21401, United States
  • Kailera Clinical Site
    Columbia, Maryland 21045, United States
  • Kailera Clinical Site
    Boston, Massachusetts 02115, United States
  • Kailera Clinical Site
    Farmington Hills, Michigan 48334, United States
  • Kailera Clinical Site
    Missoula, Montana 59804, United States
  • Kailera Clinical Site
    Lincoln, Nebraska 68516, United States
  • Kailera Clinical Site
    Las Vegas, Nevada 89148, United States
  • Kailera Clinical Site
    Albany, New York 12203, United States
  • Kailera Clinical Site
    Laurelton, New York 11413, United States
  • Kailera Clinical Site
    New York, New York 10016, United States
  • Kailera Clinical Site
    Greensboro, North Carolina 27405, United States
  • Kailera Clinical Site
    Monroe, North Carolina 28112, United States
  • Kailera Clinical Site #1
    Morehead City, North Carolina 28557, United States
  • Kailera Clinical Site #2
    Morehead City, North Carolina 28557, United States
  • Kailera Clinical Site
    Morrisville, North Carolina 27560, United States
  • Kailera Clinical Site
    Cleveland, Ohio 44122, United States
  • Kailera Clinical Site
    Chickasha, Oklahoma 73018, United States
  • Kailera Clinical Site
    East Greenwich, Rhode Island 02818, United States
  • Kailera Clinical Site
    Spartanburg, South Carolina 29303, United States
  • Kailera Clinical Site
    Chattanooga, Tennessee 37405, United States
  • Kailera Clinical Site
    Memphis, Tennessee 38119, United States
  • Kailera Clinical Site
    Amarillo, Texas 79124, United States
  • Kailera Clinical Site
    Brownsville, Texas 78526, United States
  • Kailera Clinical Site
    DeSoto, Texas 75115, United States
  • Kailera Clinical Site
    El Paso, Texas 79902, United States
  • Kailera Clinical Site
    Farmers Branch, Texas 75234, United States
  • Kailera Clinical Site
    Kingwood, Texas 77345, United States
  • Kailera Clinical Site
    Plano, Texas 75093, United States
  • Kailera Clinical Site
    Tomball, Texas 77375, United States
  • Kailera Clinical Site
    Pleasant View, Utah 84404, United States
  • Kailera Clinical Site
    Salt Lake City, Utah 84117, United States
  • Kailera Clinical Site
    Manassas, Virginia 20110, United States
  • Kailera Clinical Site
    Richmond, Virginia 23236, United States
  • Kailera Clinical Site
    Seattle, Washington 98104, United States
  • Kailera Clinical Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1120, Argentina
  • Kailera Clinical Site
    La Plata, Buenos Aires 1900, Argentina
  • Kailera Clinical Site
    Mar del Plata, Buenos Aires 7600, Argentina
  • Kailera Clinical Site
    San Nicolás de los Arroyos, Buenos Aires 2900, Argentina
  • Kailera Clinical Site
    Zárate, Buenos Aires 2800, Argentina
  • Kailera Clinical Site
    Godoy Cruz, Mendoza Province 5501, Argentina
  • Kailera Clinical Site #1
    Rosario, Santa Fe Province 2000, Argentina
  • Kailera Clinical Site #2
    Rosario, Santa Fe Province 2000, Argentina
  • Kailera Clinical Site #3
    Rosario, Santa Fe Province 2000, Argentina
  • Kailera Clinical Site #4
    Rosario, Sante Fe 2000, Argentina
  • Kailera Clinical Site #1
    Buenos Aires, 1056, Argentina
  • Kailera Clinical Site #2
    Buenos Aires, 1056, Argentina
  • Kailera Clinical Site
    Buenos Aires, 1060, Argentina
  • Kailera Clinical Site
    Buenos Aires, 1061, Argentina
  • Kailera Clinical Site
    Buenos Aires, 1128, Argentina
  • Kailera Clinical Site
    Córdoba, 5000, Argentina
  • Kailera Clinical Site
    Córdoba, 5002, Argentina
  • Kailera Clinical Site
    Bruce, Australian Capital Territory 2617, Australia
  • Kailera Clinical Site
    Blacktown, New South Wales 2148, Australia
  • Kailera Clinical Site
    Charlestown, New South Wales 2290, Australia
  • Kailera Clinical Site
    Kanwal, New South Wales 2259, Australia
  • Kailera Clinical Site
    Leichhardt, New South Wales 2040, Australia
  • Kailera Clinical Site
    Penrith, New South Wales 2750, Australia
  • Kailera Clinical Site
    Sydney, New South Wales 2100, Australia
  • Kailera Clinical Site
    Sydney, New South Wales 2228, Australia
  • Kailera Clinical Site
    Wollongong, New South Wales 2500, Australia
  • Kailera Clinical Site
    Herston, Queensland 4006, Australia
  • Kailera Clinical Site
    Morayfield, Queensland 4506, Australia
  • Kailera Clinical Site
    Camberwell, Victoria 3124, Australia
  • Kailera Clinical Site
    Melbourne, Victoria 3025, Australia
  • Kailera Clinical Site
    South Brisbane, 4101, Australia
  • Kailera Clinical Site
    Kyustendil, Kyustendil Province 2500, Bulgaria
  • Kailera Clinical Site
    Pleven, Pleven Province 5800, Bulgaria
  • Kailera Clinical Site
    Plovdiv, Plovdiv Province 4020, Bulgaria
  • Kailera Clinical Site
    Rousse, Ruse Province 7013, Bulgaria
  • Kailera Clinical Site
    Sofia, Sofia 1527, Bulgaria
  • Kailera Clinical Site
    Sofia, Sofia 1606, Bulgaria
  • Kailera Clinical Site
    Sofia, Sofia 1618, Bulgaria

Showing the first 100 of 173 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 26 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 16, 2025
StartActual
Jan 12, 2026
Primary completionEst.
Mar 27, 2028
CompletionEst.
Apr 24, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Sites
15 sites added, 9 sites removed
Show 15 added (6 Argentina, 3 United States, 2 Germany, 2 Poland, 2 Puerto Rico)
  • Kailera Clinical Site #1 · Morehead City, United States
  • Kailera Clinical Site #2 · Morehead City, United States
  • Kailera Clinical Site · Memphis, United States
  • Kailera Clinical Site #1 · Rosario, Argentina
  • Kailera Clinical Site #2 · Rosario, Argentina
  • Kailera Clinical Site #3 · Rosario, Argentina
  • Kailera Clinical Site #4 · Rosario, Argentina
  • Kailera Clinical Site #1 · Buenos Aires, Argentina
  • Kailera Clinical Site #2 · Buenos Aires, Argentina
  • Kailera Clinical Site #1 · Essen, Germany
  • Kailera Clinical Site #2 · Essen, Germany
  • Kailera Clinical Site #1 · Gdynia, Poland
  • Kailera Clinical Site #2 · Gdynia, Poland
  • Kailera Clinical Site #1 · Bayamón, Puerto Rico
  • Kailera Clinical Site #2 · Bayamón, Puerto Rico
Show 9 removed
  • Kailera Clinical Site · Morehead City, United States
  • Kailea Clinical Site · Memphis, United States
  • Kailera Clinical Site · Rosario, Argentina
  • Kailera Clinical Site · Rosario, Argentina
  • Kailera Clinical Site · Buenos Aires, Argentina
  • Kailera Clinical Site · Essen, Germany
  • Kailera Clinical Site · Gdynia, Poland
  • Kailera Clinical Site · Gdynia, Poland
  • Kailera Clinical Site · Bayamón, Puerto Rico
Oct 6, 2026
Enrollment
1156 (estimated)→1270 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    15 sites added, 9 sites removed
    Show 15 added (6 Argentina, 3 United States, 2 Germany, 2 Poland, 2 Puerto Rico)
    • Kailera Clinical Site #1 · Morehead City, United States
    • Kailera Clinical Site #2 · Morehead City, United States
    • Kailera Clinical Site · Memphis, United States
    • Kailera Clinical Site #1 · Rosario, Argentina
    • Kailera Clinical Site #2 · Rosario, Argentina
    • Kailera Clinical Site #3 · Rosario, Argentina
    • Kailera Clinical Site #4 · Rosario, Argentina
    • Kailera Clinical Site #1 · Buenos Aires, Argentina
    • Kailera Clinical Site #2 · Buenos Aires, Argentina
    • Kailera Clinical Site #1 · Essen, Germany
    • Kailera Clinical Site #2 · Essen, Germany
    • Kailera Clinical Site #1 · Gdynia, Poland
    • Kailera Clinical Site #2 · Gdynia, Poland
    • Kailera Clinical Site #1 · Bayamón, Puerto Rico
    • Kailera Clinical Site #2 · Bayamón, Puerto Rico
    Show 9 removed
    • Kailera Clinical Site · Morehead City, United States
    • Kailea Clinical Site · Memphis, United States
    • Kailera Clinical Site · Rosario, Argentina
    • Kailera Clinical Site · Rosario, Argentina
    • Kailera Clinical Site · Buenos Aires, Argentina
    • Kailera Clinical Site · Essen, Germany
    • Kailera Clinical Site · Gdynia, Poland
    • Kailera Clinical Site · Gdynia, Poland
    • Kailera Clinical Site · Bayamón, Puerto Rico
    Enrollment 1156 (estimated)→1270 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284901
Lead sponsor
Kailera
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Jan 12, 2026
Primary completion
Mar 27, 2028 (estimated)
Completion
Apr 24, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Medical Director
study director · Kailera Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion